NVX-CoV2373 COVID-19疫苗在随机安慰剂对照临床试验中的安全性
本文汇总了四项随机安慰剂对照试验中成年(≥18岁)受种者接种NVX-CoV2373 基础免疫系列的安全性数据,共纳入49,950名受试者(疫苗组30,058名,安慰剂组19,892名)。结果显示,疫苗组局部和全身征集性不良事件发生率高于安慰剂组,但多为轻至中度,严重不良事件和死亡发生率两组相似且均较低。
要点
- 疫苗组任何剂次后征集性局部反应发生率为76%,全身反应为70%。
- 疫苗组3级及以上局部反应发生率为6.28%,全身反应为11.36%。
- 严重不良事件发生率疫苗组0.91%、安慰剂组1.0%,死亡发生率分别为0.07%和0.06%。
核心结论
- NVX-CoV2373在健康成人中迄今显示出可接受的安全性特征。
研究设计与样本
- 汇总四项随机安慰剂对照临床试验中接种NVX-CoV2373基础免疫系列或安慰剂(交叉前)的成年(≥18岁)受试者,按实际接受的治疗进行分析。
主要发现
- 共纳入49,950名受试者(NVX-CoV2373组n=30,058;安慰剂组n=19,892)。
- 任何剂次后征集性局部反应发生率疫苗组76% vs 安慰剂组29%,全身反应疫苗组70% vs 安慰剂组47%,大多为轻至中度。
- 3级及以上局部反应发生率疫苗组6.28% vs 安慰剂组0.48%,全身反应疫苗组11.36% vs 安慰剂组3.58%。
- 严重不良事件发生率疫苗组0.91% vs 安慰剂组1.0%,死亡发生率疫苗组0.07% vs 安慰剂组0.06%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series demonstrated efficacy rates of 89.7-90.4 % and an acceptable safety profile. This article summarizes safety in adult recipients (aged ≥ 18 years) of primary series NVX-CoV2373 in four randomized placebo-controlled trials. METHODS: All participants who received NVX-CoV2373 primary series or placebo (pre-crossover) were included according to actual received treatment. The safety period was from Day 0 (first vaccination) to unblinding/receipt of EUA-approved/crossover vaccine, end of each study (EOS), or last visit date/cutoff date minus 14 days. The analysis reviewed local and systemic solicited adverse events (AEs) within 7 days after NVX-CoV2373 or placebo; unsolicited AEs from after Dose 1 to 28 days after Dose 2; serious AEs (SAEs), deaths, AEs of special interest, and vaccine-related medically attended AEs from Day 0 through end of follow-up (incidence rate per 100 person-years). FINDINGS: Pooled data from 49,950 participants (NVX-CoV2373, n = 30,058; placebo, n = 19,892) were included. Solicited reactions after any dose were more frequent in NVX-CoV2373 recipients (local, 76 %/systemic, 70 %) than placebo recipients (local, 29 %/systemic, 47 %), and were mostly of mild-to-moderate severity. Grade 3+ reactions were infrequent, with greater frequency in NVX-CoV2373 recipients (local, 6.28 %/systemic, 11.36 %) than placebo recipients (local, 0.48 %/systemic, 3.58 %). SAEs and deaths occurred with similarly low frequency in NVX-CoV2373 (SAEs: 0.91 %, deaths: 0.07 %) and placebo recipients (SAEs: 1.0 %, deaths: 0.06 %). INTERPRETATION: To date, NVX-CoV2373 has displayed an acceptable safety profile in healthy adults. FUNDING: Supported by Novavax, Inc.
引用
- Smith K, Hegazy K, Cai MR, et al. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials. Vaccine. 2023. PMID: 37211453. doi:10.1016/j.vaccine.2023.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。